Theme 5 Human cell biology and pathology.

摘要: Background: The delay from onset of the first symptoms to a definite ALS diagnosis depends also on elusiveness initial clinical manifestations. lack disease-specific biomarkers detect early pathology when is supposed complicates situation. This latency reduces therapeutic time frame, in which neuron-rescuing strategies exert their greatest chance work. Various are currently promised, but none them specific enough allow monitoring disease progression. This, as well heterogeneity concerning pattern and survival rates, makes difficult correct stratification patients into trials, masking potential positive outcome some patients.Objective: Our main objective establish test an diagnostic tool based microscopic immune cell patients' blood samples by using Toponome Imaging System (TIS).Methods: TIS automatically controlled device involving conjugated dye-tag incubation, protein-tag-dye-imaging, tag-dye bleaching (1). leads collection at least 21 cycle images fixated peripheral mononuclear cells (PBMCs) isolated freshly drawn healthy "control" donors. Resulting data sets contain combinatorial molecular information about spatial protein network, called toponome. PBMC toponome architectures quantitatively analyzed threshold-binary code with 1 = present 0 absent.Results: Preliminary screening PBMCs 4 reveal subpopulation lymphocytes expressing surface pattern, "ALS toponome". These aberrant T could not be found controls. We observe that number these correlate progression rate patients, supporting conclusion may causal for disease.Discussion conclusion: Although findings open up strategy monitor progression, statistical analysis many more differentiation other neurodegenerative diseases, mandatory. A trial initiated our faceALS foundation 60 classified three subsets (1. control, 2. ALS, 3. Multiple Sclerosis (MS)) close cooperation leading centres Germany still progress. detection and/or provide key understand used "staging" disease, contribute effective therapy options.